FOXO Technologies utilizes a next-generation underwriting protocol to enhance the longevity insurance sector by integrating advanced data analytics and biomarker assessments. This approach addresses the inefficiencies in traditional underwriting processes, enabling more accurate risk assessment and personalized policy offerings.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional life insurance underwriting relies on static, often incomplete, data, leading to inaccurate risk assessments and generic policy offerings. This can result in underinsured individuals and missed opportunities for personalized coverage that reflects actual longevity potential.
Solution
FOXO Technologies is developing an underwriting protocol that integrates advanced data analytics with biomarker assessments to improve the accuracy and personalization of life insurance policies. By incorporating real-time health data and biological markers of aging, FOXO aims to provide a more precise evaluation of an individual's longevity risk. This approach enables insurers to offer tailored policies that better align with individual health profiles, potentially leading to more equitable and comprehensive coverage. The technology seeks to move beyond traditional actuarial methods by incorporating molecular biology and machine learning to predict mortality risk.
Target Audience
The primary target audience includes life insurance companies seeking to enhance their underwriting processes and offer more personalized policies, as well as individuals interested in obtaining coverage that accurately reflects their health and longevity potential.
Features
- Integration of biomarker data, including epigenetic aging clocks, into risk assessment models
- Advanced data analytics platform for processing and interpreting complex health data
- Machine learning algorithms to predict mortality risk based on individual health profiles
- Personalized policy offerings based on accurate longevity predictions